
Study Single-Cell Interactions with
Unprecedented Throughput and Precision
Scribe Biosciences is an early-stage company pioneering technologies to accelerate immunotherapy discoveries through linked functional and genomic profiling of single-cell interactions.

Technology
-
Scribe Biosciences was established from technologies developed at the University of California, San Francisco to build droplet microfluidic assays with precise cell ratios.
-
Scribe's core technology, Microenvironment on Demand (MOD), enables the construction of hundreds of thousands of live cell-based assays (cytotoxicity, secretion) in droplets and selectively profile assay-positive droplets using genomics readouts.
-
MOD will enable deeper understanding of cancer, heart and autoimmune diseases by linking live-cell assays to genomics at a single-cell resolution.
Publications
Team

Russell Cole, PhD
CEO/Co-Founder



Zev Gartner, PhD
Advisor/Co-Founder
Adam Abate, PhD
Advisor/Co-Founder

Justin Madrigal, PhD
Director, Applications

Nathan Schoepp, PhD
Director, Chemistry

Bill Hyun, PhD
Investor

Paul McEwan
Investor

Lawrence Fong, MD
Scientific Advisor



Alyssa Amezquita
Associate Scientist
Job Opportunities

Please drop us a line. We are actively seeking out collaboration and pilot project opportunities.